SG11202102471XA - Use of a cathepsin s inhibitor against the formation of anti-drug antibodies - Google Patents
Use of a cathepsin s inhibitor against the formation of anti-drug antibodiesInfo
- Publication number
- SG11202102471XA SG11202102471XA SG11202102471XA SG11202102471XA SG11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA SG 11202102471X A SG11202102471X A SG 11202102471XA
- Authority
- SG
- Singapore
- Prior art keywords
- cathepsin
- formation
- drug antibodies
- inhibitor against
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18195251 | 2018-09-18 | ||
| PCT/EP2019/074918 WO2020058297A1 (en) | 2018-09-18 | 2019-09-18 | Use of a cathepsin s inhibitor against the formation of anti-drug antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102471XA true SG11202102471XA (en) | 2021-04-29 |
Family
ID=63787710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102471XA SG11202102471XA (en) | 2018-09-18 | 2019-09-18 | Use of a cathepsin s inhibitor against the formation of anti-drug antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210315863A1 (en) |
| EP (1) | EP3852880A1 (en) |
| JP (1) | JP7438198B2 (en) |
| KR (1) | KR20210061344A (en) |
| CN (1) | CN112839716A (en) |
| AR (1) | AR114732A1 (en) |
| AU (1) | AU2019344567A1 (en) |
| CA (1) | CA3112032A1 (en) |
| CR (1) | CR20210143A (en) |
| IL (1) | IL281444A (en) |
| MA (1) | MA53635A (en) |
| MX (1) | MX2021003127A (en) |
| SG (1) | SG11202102471XA (en) |
| WO (1) | WO2020058297A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110573528B (en) * | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules to costimulatory TNF receptors |
| US20210332122A1 (en) * | 2020-04-17 | 2021-10-28 | Cedars-Sinai Medical Center | Dysregulation of covid-19 receptor associated with ibd |
| WO2023245008A1 (en) * | 2022-06-13 | 2023-12-21 | Genentech, Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052027T5 (en) | 1988-11-11 | 2005-04-16 | Medical Research Council | IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING. |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US20070141059A1 (en) * | 2003-12-11 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| US9321838B2 (en) * | 2006-04-10 | 2016-04-26 | Fusion Antibodies Limited | Therapy targeting cathepsin S |
| CN101687915B8 (en) | 2007-04-03 | 2018-08-03 | 安进研发（慕尼黑）股份有限公司 | Cross-species-specific cd 3-epsilon binding domain |
| JP5518997B2 (en) * | 2009-04-20 | 2014-06-11 | エフ．ホフマン−ラ ロシュ アーゲー | Proline derivatives as cathepsin inhibitors |
| HUE055284T2 (en) | 2011-02-10 | 2021-11-29 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| US8796471B2 (en) * | 2011-11-11 | 2014-08-05 | Hoffmann-La Roche Inc. | Process for the preparation of proline derivatives |
| CA2859928A1 (en) * | 2012-02-17 | 2013-08-22 | F. Hoffmann-La Roche Ag | Novel pyrrolidine derivatives |
| WO2016034602A1 (en) * | 2014-09-05 | 2016-03-10 | F. Hoffmann-La Roche Ag | Solid forms of (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide |
| MX2018004157A (en) | 2015-10-07 | 2019-04-01 | F Hoffmann La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory tnf receptor. |
| PL3387015T3 (en) * | 2015-12-09 | 2022-02-14 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| RS59938B1 (en) * | 2016-02-26 | 2020-03-31 | Hoffmann La Roche | Novel pyrrolidine derivatives |
| AU2018359506A1 (en) | 2017-11-01 | 2020-04-23 | F. Hoffmann-La Roche Ag | Combination therapy with targeted OX40 agonists |
-
2019
- 2019-09-17 AR ARP190102617A patent/AR114732A1/en unknown
- 2019-09-18 CR CR20210143A patent/CR20210143A/en unknown
- 2019-09-18 WO PCT/EP2019/074918 patent/WO2020058297A1/en active Search and Examination
- 2019-09-18 JP JP2021515158A patent/JP7438198B2/en active Active
- 2019-09-18 MA MA053635A patent/MA53635A/en unknown
- 2019-09-18 SG SG11202102471XA patent/SG11202102471XA/en unknown
- 2019-09-18 KR KR1020217007922A patent/KR20210061344A/en unknown
- 2019-09-18 CA CA3112032A patent/CA3112032A1/en active Pending
- 2019-09-18 AU AU2019344567A patent/AU2019344567A1/en active Pending
- 2019-09-18 CN CN201980067371.2A patent/CN112839716A/en active Pending
- 2019-09-18 EP EP19768832.8A patent/EP3852880A1/en active Pending
- 2019-09-18 MX MX2021003127A patent/MX2021003127A/en unknown
-
2021
- 2021-03-11 IL IL281444A patent/IL281444A/en unknown
- 2021-03-18 US US17/206,044 patent/US20210315863A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112839716A (en) | 2021-05-25 |
| EP3852880A1 (en) | 2021-07-28 |
| JP7438198B2 (en) | 2024-02-26 |
| CR20210143A (en) | 2021-04-21 |
| US20210315863A1 (en) | 2021-10-14 |
| TW202023542A (en) | 2020-07-01 |
| MX2021003127A (en) | 2021-05-14 |
| AU2019344567A1 (en) | 2021-03-25 |
| MA53635A (en) | 2022-04-13 |
| WO2020058297A1 (en) | 2020-03-26 |
| CA3112032A1 (en) | 2020-03-26 |
| AR114732A1 (en) | 2020-10-07 |
| IL281444A (en) | 2021-04-29 |
| KR20210061344A (en) | 2021-05-27 |
| JP2022501356A (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281444A (en) | Use of a cathepsin s inhibitor against the formation of anti-drug antibodies | |
| GB201820331D0 (en) | Distributed acoustic sensing autocalibration | |
| GB201904329D0 (en) | Fluid connection deivce | |
| EP3893891A4 (en) | Solid forms of a cd73 inhibitor and the use thereof | |
| CA187829S (en) | Hand shower | |
| GB2618224B (en) | Sonic through tubing cement evaluation | |
| CA190426S (en) | Faucet body | |
| GB201819126D0 (en) | Inhibitor compounds | |
| CA185189S (en) | Faucet body | |
| GB2581174B (en) | Antibodies against hEPCR | |
| CA194355S (en) | Faucet body | |
| GB201614053D0 (en) | Determining the condition of a wound | |
| ZA201904876B (en) | Combinations of a h3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof | |
| EP3749367A4 (en) | Use of ghr-106 monoclonal antibody as a gnrh antagonist | |
| GB2571799B (en) | A navigational device | |
| GB201806573D0 (en) | A navigating device | |
| IL256730A (en) | Sensing valve | |
| IL263932A (en) | A drywall intersection finishing element | |
| IL279000A (en) | Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors | |
| GB201918931D0 (en) | Shower hose | |
| UA40563S (en) | THE PIPE IS BROKEN | |
| GB201805272D0 (en) | A sound-absorbing raft | |
| CA191646S (en) | Hand pipe | |
| GB201819845D0 (en) | Hose closure | |
| GB201801731D0 (en) | Shower Hose |